# KEYNOTE-012 (NCT01848834)

> Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01848834
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Cancer; Solid Tumor
- Interventions: Pembrolizumab
- Enrollment: 297
- Primary outcome: Number of Participants Experiencing Adverse Events (AEs)
- Primary outcome: Number of Participants Discontinuing From Study Treatment Due to an AE
- Primary outcome: Overall Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Response Rate Based on Blinded Independent Central Radiology (BICR) Review (Cohorts A, B, C, and D)
- Primary outcome: Overall RECIST 1.1 Response Rate Based on BICR Review for Participants in Cohort B2

## Indexed commentary on KEYNOTE-012 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 6
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-012-nct01848834

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01848834", "email": "<work email>"}; the inbox owner confirms by the emailed link.